Recent reports have identified CTSCs, which have CSC-like potential and enhanced metastatic capacity in various solid tumors, such as breast [23], colon [24], and hepatocellular carcinoma [25], using a combination of EpCAM and CSC markers in the each tumor (e.g., CD44 or CD133). This evidence concerns the gene EPCAM and hepatocellular carcinoma.